双环醇片治疗慢性乙型病毒性肝炎的评价

Use of bicyclol in treatment of chronic hepatitis B virus infection： a systematic review

目的评价双环醇片治疗成人慢性病毒性乙型肝炎的疗效与安全性。方法计算机检索中国生物医学文摘数据库，中国期刊全文数据库，和中文科技期刊数据库及PubMed等数据库，纳入比较双环醇片与非特异性治疗、干扰素、拉米夫定治疗慢性乙型病毒性肝炎患者的随机临床试验。纳入试验的质量由两名评价员独立评价。试验数据的统计分析采用Cochrane协作网提供的RevMan4．2软件进行。结果最终纳入14个临床试验1782例患者。ALT复常率双环醇组（69．3％）高于对照组（59．0％），（P=0．04），HBeAg阴转率双环醇组（22．1％）高于对照组（13．5％），（P〈0．00001）。没有严重不良事件报道。结论双环醇促进慢性病毒性乙型肝炎患者的肝功能恢复，对血清病毒标志物清除可能有一定效果。

Objective To evaluate the efficacy and safety of bicycle for chronic hepatitis B. Method The authors searched CBMDisk, CJFD （ 2000-2006 ）, CJD：CD, PubMed （ 1966-2006 ） For randomized controlled trials （RCT） comparing bicyclol versus non-antiviral interventions, interferon alpha （IFN-α） and lamivudine for treatment of chronic hepatitis B. Two reviewers performed data extraction and quality assessment independently and discussed when there was different opinion. We analyzed the data with RevMan 4.2 software supplied by Cochrone Collabration. Results Fourteen RCTs involving 1782 patients were included. ALT recovery rate of bicyclol group was 69.3% while that of the control group was 59.0% , P = 0.04. Loss of HBeAg in the bicyclol group （22.1% ） was higher than that of the control group （ 13.5 % ）, P 〈 0. 000 01. No serious adverse events were reported. Conclusion Bicyclol might be benefitial to recovery of liver function and loss of serum HBV marker.